BS_D144EJRQ
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 26.741130091984232
- age_years
- 2.085
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.544
- MYC_TARGETS_V1+0.512
- G2M_CHECKPOINT+0.488
- E2F_TARGETS+0.479
- DNA_REPAIR+0.282
- UNFOLDED_PROTEIN_RESPONSE+0.262
- WNT_BETA_CATENIN_SIGNALING+0.249
- TGF_BETA_SIGNALING+0.165
- MITOTIC_SPINDLE+0.106
- SPERMATOGENESIS+0.098
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.514
- INTERFERON_GAMMA_RESPONSE-0.474
- APICAL_SURFACE-0.428
- TNFA_SIGNALING_VIA_NFKB-0.424
- INFLAMMATORY_RESPONSE-0.418
- IL6_JAK_STAT3_SIGNALING-0.407
- ALLOGRAFT_REJECTION-0.382
- MYOGENESIS-0.378
- HYPOXIA-0.366
- ESTROGEN_RESPONSE_LATE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M86ECPHK | Embryonal tumors | — | 0.946 |
| 2 | BS_HE57E1RP | medulloblastoma | — | 0.943 |
| 3 | BS_TZVFR600 | medulloblastoma | — | 0.942 |
| 4 | BS_GCQFGDTX | medulloblastoma | — | 0.942 |
| 5 | BS_HZE3KYZ1 | medulloblastoma | — | 0.939 |
| 6 | BS_V72H4RQS | medulloblastoma | — | 0.936 |
| 7 | ERR2278885 | — | — | 0.934 |
| 8 | BS_TV5B86ZD | Embryonal tumors | — | 0.931 |
| 9 | BS_JFB984RG | medulloblastoma | — | 0.930 |
| 10 | BS_5P1TN10Z | Embryonal tumors | — | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.544 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.512 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.488 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.479 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.282 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.262 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.249 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.165 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.106 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.098 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.078 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.067 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.031 | Inavolisib | — uncovered |